Long-Term Outcomes and Persistent Toxicities Following BRAF/MEK Inhibitor Therapy for Advanced Melanoma

Recent studies have shown that approximately 20% of patients have 4-5 year PFS on BRAF/MEK inhibitors. The long-term safety and efficacy in these patients with more durable responses have not been studied.

Source: European Journal of Cancer - September 22, 2023 Category: Cancer & Oncology Authors: Rachel S. Goodman, Lorenza Di Guardo, Andrea Maurichi, Brendan Kirwin, Adnan Muhammad Khattak, Vito Vanella, Joanna Lee, Aleigha Lawless, Juliane Andrade Czapla, Andrea Spagnoletti, Margherita Ambrosini, Elisabeth Livingstone, Georgina V. Long, Ryan J. Su Tags: Original Research Source Type: research